SCYNEXIS Company Profile (NASDAQ:SCYX)

About SCYNEXIS

SCYNEXIS logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SCYX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.49
  • 50 Day Moving Average: $3.32
  • 200 Day Moving Average: $3.33
  • 52-Week Range: $23,990,000.00 - $1.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.28
  • P/E Growth: 0.00
  • Market Cap: $86.84M
  • Outstanding Shares: 23,990,000
  • Beta: 0.3
Profitability:
  • Net Margins: -13,335.88%
  • Return on Equity: -83.00%
  • Return on Assets: -62.52%
Debt:
  • Debt-to-Equity Ratio: 0.43%
  • Current Ratio: 13.45%
  • Quick Ratio: 13.45%
Additional Links:
Companies Related to SCYNEXIS:

Analyst Ratings

Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (?)
Ratings Breakdown: 6 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.14)
Consensus Price Target: $12.29 (239.38% upside)

Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017AegisInitiated CoverageBuy$7.00View Rating Details
11/12/2016HC WainwrightReiterated RatingBuyView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy -> Strong-Buy$8.00View Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00View Rating Details
8/17/2016GuggenheimInitiated CoverageBuy$15.00View Rating Details
8/9/2016Needham & Company LLCLower Price TargetBuy$16.00 -> $10.00View Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyView Rating Details
11/16/2015Royal Bank Of CanadaLower Price TargetOutperform$18.00 -> $17.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for SCYNEXIS (NASDAQ:SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
8/8/2016Q216($0.52)($0.56)ViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)ViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)ViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)ViewN/AView Earnings Details
11/13/2014($0.53)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)
Current Year EPS Consensus Estimate: $-1.83 EPS
Next Year EPS Consensus Estimate: $-1.59 EPS

Dividends

Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for SCYNEXIS (NASDAQ:SCYX)
Insider Ownership Percentage: 3.91%
Institutional Ownership Percentage: 47.81%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.00View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.00View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.00View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
DateHeadline
News IconScynexis Inc SCYX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:SCYX)
www.bioportfolio.com - February 18 at 8:32 AM
News IconA look at SCYNEXIS, Inc. (SCYX)'s track record of earnings - Post Analyst (NASDAQ:SCYX)
postanalyst.com - February 13 at 8:28 AM
News IconTale of the Tape: Technical Recap for Scynexis Inc (SCYX) - Rives Journal (NASDAQ:SCYX)
rivesjournal.com - February 11 at 7:49 PM
biz.yahoo.com logoSCYNEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:SCYX)
biz.yahoo.com - February 9 at 2:54 AM
seekingalpha.com logoMicrocap Scynexis' Antifungal Treatments Have Outsized Potential - Seeking Alpha (NASDAQ:SCYX)
seekingalpha.com - February 8 at 5:31 AM
finance.yahoo.com logoSCYNEXIS, Inc. to Participate in Upcoming Investor Conferences (NASDAQ:SCYX)
finance.yahoo.com - January 31 at 10:48 PM
News IconTicker Tracker: Looking at Scynexis Inc (SCYX) - Rives Journal (NASDAQ:SCYX)
rivesjournal.com - January 29 at 8:14 AM
News IconSCYNEXIS, Inc. Release: Company Announces Appointment Of Industry Veteran To Its Board Of Directors (NASDAQ:SCYX)
www.biospace.com - January 28 at 7:51 PM
streetinsider.com logoScynexis (SCYX) Appoints Marion McCourt to Board of Directors (NASDAQ:SCYX)
www.streetinsider.com - January 28 at 6:31 AM
seekingalpha.com logoSCYNEXIS, Inc. (SCYX) (NASDAQ:SCYX)
seekingalpha.com - January 28 at 6:31 AM
News IconWhat Are the Technicals Saying About These Shares: Scynexis Inc (SCYX) - Sherwood Daily (NASDAQ:SCYX)
sherwooddaily.com - January 27 at 2:56 AM
streetinsider.com logoScynexis (SCYX) Appoints Marion McCourt to Board of Directors - StreetInsider.com (NASDAQ:SCYX)
www.streetinsider.com - January 27 at 2:56 AM
News IconAre Insiders Filling Their Own Pockets With Shares? Insider Update on SCYNEXIS, Inc. (NASDAQ:SCYX) - Wall Street Beacon (NASDAQ:SCYX)
wsbeacon.com - January 23 at 8:07 PM
News IconStock Perspective: SCYNEXIS, Inc. (NASDAQ:SCYX) Earnings in View - Aiken Advocate (NASDAQ:SCYX)
aikenadvocate.com - January 23 at 8:07 PM
News IconEarnings According to Analysts for SCYNEXIS, Inc. (NASDAQ:SCYX)? - Aiken Advocate (NASDAQ:SCYX)
aikenadvocate.com - January 16 at 1:30 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: SCYNEXIS, Inc. (NASDAQ:SCYX) - Wall Street Beacon (NASDAQ:SCYX)
wsbeacon.com - January 14 at 7:47 PM
News IconScynexis Inc SCYX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SCYX)
www.bioportfolio.com - January 11 at 10:41 PM
thestreet.com logoMajor Indices' Support Holds, But Momentum Eases (NASDAQ:SCYX)
realmoney.thestreet.com - January 9 at 9:47 PM
News IconScynexis Inc. (SCYX) Stock Moves Down and Here's Why - The Ledger Gazette (NASDAQ:SCYX)
ledgergazette.com - December 29 at 12:38 AM
News IconMy Watchlist for Wednesday, December 28 (NASDAQ:SCYX)
ac-investor.blogspot.com - December 27 at 7:24 PM
News IconADX Watch on Shares of Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - December 20 at 8:34 PM
capitalcube.com logoETFs with exposure to SCYNEXIS, Inc. : December 19, 2016 (NASDAQ:SCYX)
www.capitalcube.com - December 20 at 2:34 PM
News IconCCI, ADX, and Williams %R Review for Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - December 18 at 1:23 AM
us.rd.yahoo.com logo8:02 am Scynexis has identified an IV formulation and dose regimen that, pending discussions with the FDA, co plans to test in the upcoming clinical trials of SCY-078 (NASDAQ:SCYX)
us.rd.yahoo.com - December 14 at 1:14 AM
247wallst.com logoSCYNEXIS Clinical Update Does Not Ruffle Any Feathers - 24/7 Wall St. (NASDAQ:SCYX)
247wallst.com - December 13 at 8:11 PM
finance.yahoo.com logoSCYNEXIS Clinical Update Does Not Ruffle Any Feathers (NASDAQ:SCYX)
finance.yahoo.com - December 13 at 8:11 PM
News IconReady for an Upsurge? Analysts Chime in on SCYNEXIS, Inc. (NASDAQ:SCYX) - Prospect Journal (NASDAQ:SCYX)
prospectjournal.com - December 13 at 8:07 AM
finance.yahoo.com logoSCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections (NASDAQ:SCYX)
finance.yahoo.com - December 13 at 8:07 AM
News IconTechnical Action Update on Shares of Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - December 13 at 12:54 AM
finance.yahoo.com logoSCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference (NASDAQ:SCYX)
finance.yahoo.com - December 12 at 7:50 PM
insidermonkey.com logoSCYNEXIS Inc (SCYX): Have Hedge Funds Found A Hidden Gem? (NASDAQ:SCYX)
www.insidermonkey.com - December 11 at 9:02 AM
News IconInvestor Box: Viewing Levels on Shares of Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - December 10 at 6:55 PM
News IconTrading Scope: Following Levels on Shares of Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - December 10 at 8:22 AM
News IconCan This Stock Gain Traction: SCYNEXIS, Inc. (NASDAQ:SCYX) - Prospect Journal (NASDAQ:SCYX)
prospectjournal.com - December 6 at 7:22 PM
News IconDirectional Index Update on Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - December 6 at 7:22 PM
nasdaq.com logoSCYNEXIS (SCYX) Shares March Higher, Can It Continue? - Nasdaq (NASDAQ:SCYX)
www.nasdaq.com - December 2 at 7:20 PM
finance.yahoo.com logoSCYNEXIS (SCYX) Shares March Higher, Can It Continue? (NASDAQ:SCYX)
finance.yahoo.com - December 1 at 7:37 PM
News IconChart Focus: Eye on Technicals for Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - November 28 at 4:01 PM
News IconTechnical Updates on Shares of Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - November 27 at 3:50 PM
News IconValue Composite Score Update on SCYNEXIS, Inc. (NASDAQ:SCYX) - Wall Street Lion (NASDAQ:SCYX)
wslnews.com - November 23 at 10:35 AM
News IconTrading Sheet: Tracking Technicals for Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - November 23 at 10:35 AM
News IconWhat is the Sell-side Saying About SCYNEXIS, Inc. (NASDAQ:SCYX)? - CSZ News (NASDAQ:SCYX)
cincysportszone.com - November 22 at 11:59 AM
News IconFocusing on the Charts for Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - November 22 at 11:59 AM
News IconInvestor Review: Focusing in on Shares of Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - November 20 at 7:02 PM
News IconRelative Strength Index Check on Scynexis Inc (SCYX) - MicroCap Wired (NASDAQ:SCYX)
www.microcapwired.com - November 18 at 6:58 PM
News IconTrading Views: Checking the Numbers for Scynexis Inc (SCYX) - Yankee Analysts (NASDAQ:SCYX)
yankeeanalysts.com - November 16 at 7:40 PM
News IconTechnical Study: Following Indicators for Scynexis Inc (SCYX) - MicroCap Wired (NASDAQ:SCYX)
www.microcapwired.com - November 16 at 7:40 PM
finance.yahoo.com logoSCYNEXIS INC Financials (NASDAQ:SCYX)
finance.yahoo.com - November 16 at 7:40 PM
News IconTracking Williams %R for Scynexis Inc (SCYX) - MicroCap Wired (NASDAQ:SCYX)
www.microcapwired.com - November 14 at 7:40 PM
News IconSCYNEXIS, Inc. (SCYX) Analyst Review - NewsDen (NASDAQ:SCYX)
newsden.net - November 12 at 7:22 PM

Social

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2017?

7 brokerages have issued twelve-month price targets for SCYNEXIS's shares. Their forecasts range from $7.00 to $16.00. On average, they expect SCYNEXIS's stock price to reach $12.29 in the next twelve months.

When will SCYNEXIS announce their earnings?

SCYNEXIS is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about SCYNEXIS stock?

Here are some recent quotes from research analysts about SCYNEXIS stock:

  • Aegis analysts commented, "We are initiating coverage of Scynexis with a Buy rating and a price target of $7 per share. Scynexis is a clinical stage biotechnology company developing a new class of anti-fungal drugs. The lead molecule, SCY-078, has the same target as the current echinocandin class but can be formulated for both oral or intravenous administration. It is a structurally different molecule with different pharmacological properties and not simply an oral version of an existing drug. Clinical testing has shown SCY-078 has a broader spectrum of activity than the current echinocandins, including efficacy against the mutated fungal strains that resist treatment and are making the current drugs ineffective." (1/31/2017)
  • According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (12/28/2016)

  • Brean Capital analysts commented, "EPZM reported Q1 financials." (5/9/2016)

Who owns SCYNEXIS stock?

SCYNEXIS's stock is owned by a number of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (14.21%), Broadfin Capital LLC (6.16%), FMR LLC (5.55%), Deerfield Management Co. (4.37%), Highland Capital Management LP (1.72%) and Perceptive Advisors LLC (0.71%). Company insiders that own SCYNEXIS stock include Ann Hanham, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado.

Who sold SCYNEXIS stock? Who is selling SCYNEXIS stock?

SCYNEXIS's stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, FMR LLC and FT Options LLC.

Who bought SCYNEXIS stock? Who is buying SCYNEXIS stock?

SCYNEXIS's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought SCYNEXIS stock in the last two years include Ann Hanham, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado.

How do I buy SCYNEXIS stock?

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of SCYNEXIS stock cost?

One share of SCYNEXIS stock can currently be purchased for approximately $3.62.

SCYNEXIS (NASDAQ:SCYX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for SCYNEXIS (NASDAQ:SCYX)

Earnings History Chart

Earnings by Quarter for SCYNEXIS (NASDAQ:SCYX)

Dividend History Chart

Dividend Payments by Quarter for SCYNEXIS (NASDAQ:SCYX)

Last Updated on 2/19/2017 by MarketBeat.com Staff